Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjustment of insulin degludec to reduce post-exercise nocturnal hypoglycaemia (ADREM)
2019-004222-22Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin degludec in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Radboud University Medical Center. Primary endpoint: Time in nocturnal hypoglycaemic range. Started Dec 2019; status: completed.
02
Drugs
insulin degludec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2019-004222-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004222-22.